Lupin Limited announced on August 12 that it has entered into a licensing and commercialization agreement with Switzerland-based Sandoz Group AG for its biosimilar Ranibizumab. The deal covers multiple regions, including the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.
Under the agreement, Lupin will handle manufacturing and regulatory submissions, while Sandoz will oversee commercialization. Sandoz will hold exclusive marketing rights in most designated markets, except for France, Australia, Vietnam, and Malaysia, where rights will be semi-exclusive. In a separate arrangement, Sandoz will acquire sole commercialization rights for Canada.
Ranibizumab is a monoclonal antibody fragment that binds to and inhibits VEGF-A, used in treating conditions such as Neovascular (Wet) Age-Related Macular Degeneration, Diabetic Macular Edema, Proliferative Diabetic Retinopathy, and other retinal diseases.
Thierry Volle, President EMEA and Emerging Markets at Lupin, said the partnership aligns with both companies’ vision to expand global access to advanced biologic therapies and improve outcomes for underserved patients.
Lupin, a global pharmaceutical leader headquartered in Mumbai, has a presence in over 100 markets, with 15 manufacturing sites and seven research centers worldwide.
